ScreenerHero

FUM Futura Medical plc

LSE · GB · Healthcare · Biotechnology · futuramedical.com
0.2100GBp-4.55%Mkt Cap: 3.38M $P/E: —

Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical treatment for erectile dysfunction. It also develo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
ARGENX SE
$55.45BUSDP/E 35.2
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$42.34BUSDP/E 18.1
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
GMAB
Genmab A/S
$20.52BUSDP/E 27.1
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap3.38M USD
Enterprise Value37.79K USD
Revenue (TTM)2.52M USD
Gross Profit1.35M USD
Net Income (TTM)-9.86M USD
Revenue/Share0.0050 GBp
Last Price0.2100 GBp
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB0033278473
Valuation
P/E (Trailing)—
P/E (Forward)-0.29
PEG—
EV/EBITDA-0.01
EV/Revenue0.02
P/S1.41
P/B0.73
EPS (TTM)-0.01
EPS (Forward)-0.01
52W Range
0.18001% of range4.490
52W High4.490 GBp
52W Low0.1800 GBp
Profitability
Gross Margin73.08%
Oper. Margin-73.78%
EBITDA Margin-128.41%
Profit Margin-534.62%
ROE-323.35%
ROA-173.80%
Growth
Revenue Growth62.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.10M USD
CapEx (TTM)—
FCF Margin-127.80%
FCF Yield-95.12%
Net Debt-1.35M USD
Net Debt/EBITDA0.42
Balance Sheet
Debt/Equity—
Current Ratio1.82
Quick Ratio1.82
Book Value/Sh0.0030 GBp
Cash/Share0.0020 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 GBp
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.48B
Float510.43M
Insiders24.29%
Institutions10.56%
Technical
SMA 500.3183 (-34.0%)
SMA 2000.8022 (-73.8%)
Beta-0.00
S&P 52W Chg14.58%
Avg Vol (30d)10.76M
Avg Vol (10d)16.49M
Technical Indicators
RSI (14)41.8
MACD-0.0365
MACD Signal-0.0438
MACD Hist.+0.0073
BB Upper0.2697 GBp
BB Middle0.2190 GBp
BB Lower0.1682 GBp
BB Width46.39%
ATR (14)0.0584 GBp
Vol Ratio (20d)0.63x